ロード中...
Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer
High-grade serous ovarian cancer (HGSOC) is the predominant and most lethal histological type of epithelial ovarian cancer. During the last few years, several new treatment options with PARP inhibitors have emerged. The FDA has approved the PARP inhibitor olaparib (Lynparza™) as maintenance treatmen...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6916751/ https://ncbi.nlm.nih.gov/pubmed/31857852 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27363 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|